CD274 and non-small cell lung carcinoma: Bintrafusp alfa, a bifunctional fusion protein that inhibits TGF-βRII and blocks PD-L1, has shown positive clinical outcomes in second-line therapy for NSCLC and first-line treatment for cervical cancer patients (128).